QUILT-3.005: A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma

Clinical Trial ID NCT02099539

Rank	Title	Journal	Year	PubWeight™‹?›
1	Targeting natural killer cells in cancer immunotherapy.	Nat Immunol	2016	1.06
2	The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas.	Clin Cancer Res	2015	0.98
3	Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models.	Cancer Immunol Res	2015	0.96
4	A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.	PLoS Pathog	2016	0.90
5	IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy.	Cancer Res	2015	0.81
6	Improving natural killer cell cancer immunotherapy.	Curr Opin Organ Transplant	2015	0.80
7	The Role of Immunotherapy in Multiple Myeloma.	Pharmaceuticals (Basel)	2016	0.77
8	A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses.	J Biol Chem	2016	0.76
9	Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.	J Mol Med (Berl)	2015	0.75